Author Archives:

3 Day Pharma Mini MBA Training Course (Mar 18th – Mar 20th, 2026) – ResearchAndMarkets.com

Posted on by

3 Day Pharma Mini MBA Training Course (Mar 18th – Mar 20th, 2026) – ResearchAndMarkets.com




3 Day Pharma Mini MBA Training Course (Mar 18th – Mar 20th, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Pharma Mini MBA Training Course (Mar 18th – Mar 20th, 2026)” training has been added to ResearchAndMarkets.com’s offering.


Working in the highly competitive pharmaceutical industry, with ever-increasing change and pressure, is probably one of the most challenging managerial roles of any industry today. This event has been especially designed to help you transcend these challenges by training you to become equipped to see the bigger picture in all aspects of your role. It will help you build your management skills for the future and prepare you to fulfil your ambitions.

The Pharma Mini MBA accelerated management programme is a distillation of the most valuable parts of an MBA, as applied to the pharmaceutical industry. It will provide you with practical management tools to apply in the workplace, as well as giving a real taste of an MBA course with pharmaceutical case studies from business schools.

Pharmaceutical industry context – business school pharmaceutical case studies on each module

This intensive three-day course will help you to translate your learning into new behaviours and improvements in your capability and performance and will work through live issues impacting on the industry and on you directly. The individual and group exercises will focus on pharmaceutical/biopharma/generic MBA case studies, and also on your own challenges and examples. The business school case studies will help give the ‘feel’ of a full MBA and help you understand more about the strategies used in today’s pharmaceutical and associated industries.

The Pharma Mini MBA is also an invaluable guide to all that is best and most practical on an MBA course – with specific focus on the pharmaceutical sector. It is also of value either to gain the most useful aspects of an MBA or as an MBA taster, providing a foundation of the essential MBA elements to apply directly to your role. The pharmaceutical industry requires employees to focus on successful leadership and business management skills, which this programme is designed to give you.

Key benefits of attending

MBA learning style of the programme

The Pharma Mini MBA learning style is ‘hands-on’ rather than academic. The programme is very practical, without being too theoretical, with industry-relevant case studies drawn from business school cases. The course covers the key areas of an MBA and applies these MBA tools and concepts to the pharmaceutical industry, providing you with a firm foundation of the essential MBA thinking and terminology. Three modules will be covered in just three days of interactive workshops to enhance the value of the course and, to minimise your time away from the office, the programme director also sets optional pre- and post-course work.

  • Develop your understanding of the key techniques of an MBA to apply to your work
  • Gain a greater understanding of the pharma industry, its drivers, challenges and opportunities
  • Hear about the latest strategic technology innovations being used and developed in the pharma industry
  • Understand what strategic thinking is and how to use strategy tools
  • Develop your leadership and strategic skills
  • Become more effective in coping with and managing change in the pharma industry
  • Explore the benefits and costs of doing an MBA
  • Take away a Mini MBA toolkit to apply to your job
  • Discuss and learn from real pharma industry case studies

Pre-course work (sent out to delegates prior to the course)

  • Diagnostic questionnaire – your strategic competencies
  • Discussions of diagnostic output/other areas of value

Certifications:

  • CPD: 18 hours for your records
  • Certificate of completion

Who Should Attend:

A ‘must-attend’ for professionals in the pharmaceutical/biopharma/medical device/animal health industries wishing to develop their business management skills for more senior levels and beyond mere technical ability. It will also help anyone thinking of studying for an MBA who would like an idea of what is involved. It is particularly beneficial to attend with a colleague to maximise the practical learning.

Key Topics Covered:

Day 1

Strategy and strategic challenges in the pharma industry

  • Strategy and strategic thinking and their importance in the pharma industry
  • Strategic analysis, planning and implementation

    • Environmental analysis
    • Understanding the competitive environment
    • Strategic options
  • Applying the MBA toolkit
  • Stakeholders and their expectations in the pharma industry
  • Obtaining the value out of strategy in the pharma industry

Day 2

Commercial management and leadership in the pharma industry

  • New product development and the target product profile
  • Portfolio management used in the pharma industry
  • Understanding business performance
  • The business plan
  • Diagnosing specific performance problems
  • Developing strategic alliances and collaborations in the pharma industry
  • Benefits, costs of doing an MBA and the different routes
  • The role of leadership

    • What are the core competencies of effective leaders in pharma?
    • Leadership vs management
    • Leadership style and approaches in the pharma industry

Managing innovation in the pharma industry

  • Innovation approaches currently being adopted along the pharma value chain
  • Future innovations in pharma and the life science industries

Day 3

Hot topics in market access strategy

Leading and implementing pharma strategy and change

  • Leading successful change

    • Diagnosis around change
    • How to create the conditions for successful change
    • Why people resist change and how to manage this
    • Change management including leading a structural reorganisation
    • Creating a team, department and organisation relevant to today’s pharma business needs
    • Team formation and development
  • Implementing strategy and change, essentials of planning and managing projects

    • Project management tools and techniques to use in implementing pharma projects
    • Applying key project management techniques to pharma projects
    • Understanding of cultural awareness to work more effectively with pharma colleagues

Practical application/review

  • Personal development action plan to apply the learning within your own organisation
  • Revisiting your competency assessment – what has shifted?
  • Recommended further reading
  • Practical application of tools (toolkit)

Speakers:

Leela Barham

Health Economist and Policy Expert

Independent (Freelance)

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis. This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team. She has more than 10 years experience in the pharmaceutical industry – both at home and abroad – and has worked for all stakeholders in the health care system ranging from patient organisations, the National Health Service, health insurers, and the pharmaceutical industry.

She has particular expertise in public and patient involvement, Patient Access Schemes/risk sharing schemes, the Cancer Drugs Fund, policy on Health Technology Assessment (HTA), and the Pharmaceutical Price Regulation Scheme (PPRS). She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement. She has also had her research published in peer review journals including The Patient and Pharmacoeconomics.

Oguz Ozden

Strategy Consultant

PwC

Oguz is a strategy consultant in PwC’s Strategy& practice, leading large, complex and international transformations across the Pharma and Life Sciences sector. He has over 10 years of consulting experience in the sector having worked across various functions in Biotech, Pharma and Consumer Health as well as Pharmaceutical Wholesale.

Laura Brown

Pharmaceutical QA and Training Consultant

University of Cardiff

Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years’ experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International. She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including “The Planning of International Drug Development”, in the Clinical Research Manual, Euromed and the “Impact of Brexit”, RQA Journal 2017.

For more information about this training visit https://www.researchandmarkets.com/r/107v1d

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Cell Therapy Processing Global Markets and Technology Analysis Report 2025-2030 – ResearchAndMarkets.com

Posted on by

Cell Therapy Processing Global Markets and Technology Analysis Report 2025-2030 – ResearchAndMarkets.com




Cell Therapy Processing Global Markets and Technology Analysis Report 2025-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Processing: Global Markets and Technologies” report has been added to ResearchAndMarkets.com’s offering.


The global market for cell therapy processing is estimated to grow from $2.7 billion in 2025 to reach $7.1 billion by 2030, at a compound annual growth rate (CAGR) 21.4% from 2025 to 2030.

According to the American Society of Gene and Cell Therapy (ASGCT), cell therapy is a therapeutic approach in which patients are given either normal or altered cells to treat illnesses. In this treatment, patients receive injections of intact, living human cells that are thought to have therapeutic potential.

The foundation of cell treatments is the idea that cells can be genetically reprogrammed to fight various illnesses, either by using the patient’s own cells (autologous) or cells from a healthy donor (allogeneic). These treatments, such as small-molecule medications, have become strong substitutes for conventional therapy. It is important to note that there have been numerous advances in this field over the last few decades, especially in the production process for cell therapy.

The report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social and corporate governance (ESG) developments. It includes an analysis of the competitive landscape and has a dedicated section of company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.

The report includes:

  • 32 data tables and 58 additional tables
  • An overview of the global market and technologies for cell therapy processing
  • In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
  • Evaluation of the current market size and revenue growth prospects specific to the cell therapy processing, accompanied by a market share analysis by offerings, application and region
  • Analysis of current and future demand in the global cell therapy processing market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
  • Analysis of drivers, challenges and opportunities affecting market growth
  • Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios and ESG trends of the market
  • Market share analysis of the key market participants in the cell therapy processing market, along with their research priorities, product portfolios, global rankings and company competitive landscape
  • Profiles of the major companies, including Thermo Fisher Scientific Inc., Danaher Corp., Lonza, Miltenyi Biotech and Sartorius AG

Companies Featured

  • Bio-Techne
  • Biospherix LLC
  • Cytiva
  • Fresenius Kabi AG
  • Fujifilm Biosciences
  • Lonza
  • Merck KGaA
  • Miltenyi Biotec
  • Proteintech Group Inc.
  • Revvity
  • Sartorius AG
  • Stemcell Technologies
  • Terumo Corp.
  • Thermo Fisher Scientific Inc.
  • Thermogenesis

Key Attributes:

Report Attribute Details
No. of Pages 125
Forecast Period 2025 – 2030
Estimated Market Value (USD) in 2025 $2.7 Billion
Forecasted Market Value (USD) by 2030 $7.1 Billion
Compound Annual Growth Rate 21.4%
Regions Covered Global

Key Topics Covered:

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Overview
  • Current Market Scenario
  • Segmental Analysis
  • Regional Market Insights
  • Emerging Technologies
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Cell Therapy Manufacturing Process
  • Cell Therapy Supply Chain
  • Macroeconomic Factors Analysis
  • Demographic Factors
  • Geopolitical Factors
  • Impact of U.S. Tariffs
  • Porter’s Five Forces Analysis

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Growing Demand for Regenerative Medicine
  • Increasing Investments in Cell and Gene Therapy (CGT) Research
  • Expanding Clinical and Commercial Activities
  • Growing Number of Strategic Initiatives
  • Rising Aging Population and the Increasing Prevalence of Chronic Diseases
  • Market Restraints
  • Complex Manufacturing and Supply Chain
  • High Cost of Development
  • Lack of Skilled Workforce
  • Regulatory Hurdles
  • Market Opportunities
  • Decentralized Manufacturing
  • Shift Toward Allogeneic Therapies

Chapter 4 Regulatory Landscape

  • Overview
  • Regulatory Scenario by Country/Region
  • U.S. FDA
  • Europe
  • Asia-Pacific

Chapter 5 Emerging Technologies and Developments

  • Key Takeaways
  • Automation
  • First-Generation Automated Platforms
  • Second-Generation Automated Platforms
  • Single-Use Technologies and Miniaturization

Chapter 6 Market Segment Analysis

  • Overview
  • Segmentation Breakdown
  • Market Analysis by Type of Offerings
  • Key Takeaways
  • Products
  • Services
  • Software
  • Market Analysis by Application
  • Key Takeaways
  • Cancer
  • Musculoskeletal Disorders (Bone and Skeletal Muscle Repair)
  • Neurological Disorders
  • Cardiovascular Disorders
  • Others
  • Geographic Breakdown
  • Market Analysis by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 7 Competitive Intelligence

  • Key Takeaways
  • Competitive Analysis
  • Strategic Initiatives
  • Agreements, Collaborations and Partnerships
  • Acquisitions
  • Investments and Expansions

Chapter 8 Sustainability in Cell Therapy Processing Market: An ESG Perspective

  • Introduction to ESG
  • Sustainability in the Cell Therapy Processing Industry
  • Environmental Factors
  • Social Factors
  • Governance Factors
  • ESG Sustainability Trends and Initiatives
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • ESG Risk Ratings
  • Concluding Remarks

For more information about this report visit https://www.researchandmarkets.com/r/u5ecg4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Immunotherapy Drugs Global Markets Report 2025: Historical Revenue Data for 2022-2024, Estimate Figures for 2025, and Forecasts for 2030 – ResearchAndMarkets.com

Posted on by

Immunotherapy Drugs Global Markets Report 2025: Historical Revenue Data for 2022-2024, Estimate Figures for 2025, and Forecasts for 2030 – ResearchAndMarkets.com




Immunotherapy Drugs Global Markets Report 2025: Historical Revenue Data for 2022-2024, Estimate Figures for 2025, and Forecasts for 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Immunotherapy Drugs: Global Markets” report has been added to ResearchAndMarkets.com’s offering.


The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.

Despite challenges, the immunotherapy field is rapidly evolving, with researchers developing more effective approaches such as personalized cancer vaccines and oncolytic viruses. Immunotherapy has demonstrated its potential for multiple diseases, particularly cancer, with ongoing research likely to yield even more effective and personalized therapies.

The current report provides detailed information on immunotherapy drugs. It analyzes the market trends with data from 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030, including regional markets for immunotherapy drugs. This report highlights the current and future market potential and provides a detailed discussion on the competitive environment. The report will also cover regulatory scenarios, drivers, restraints and opportunities. Additionally, it covers market share data for key companies.

The report aims to:

  • Analyze types of immunotherapies.
  • Analyze global market size and segmentation.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts through 2030.
  • Assess market shares, competitiveness and industry structure.
  • Identify potential long-term impacts on the immunotherapy drug market.

The report includes:

  • 88 data tables and 57 additional tables
  • An overview of the global market for immunotherapy drugs
  • In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, and forecasts for 2030, including projections of CAGRs through 2030
  • Evaluation of the current market size and revenue growth prospects specific to the immunotherapy drugs, accompanied by a market share analysis by therapy type, application and region
  • Description of immunotherapy and combination immunotherapy, and discussion of how it targets cell-mediated adaptive immunity
  • Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and new targeted approaches for immunotherapy
  • Analysis of the current and future demands in the global immunotherapy drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
  • Analysis of drivers, challenges and opportunities affecting the market’s growth
  • Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
  • Market share analysis of the key companies in the immunotherapy drugs, along with their research priorities, product portfolios, global rankings and the competitive landscape
  • Profiles of major companies in industry, including: F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, and Sanofi

Companies Featured

  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Gsk PLC.
  • Johnson & Johnson Services Inc.
  • Lilly
  • Merck & Co.Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

Key Attributes:

Report Attribute Details
No. of Pages 231
Forecast Period 2025 – 2030
Estimated Market Value (USD) in 2025 $260.7 Billion
Forecasted Market Value (USD) by 2030 $467.4 Billion
Compound Annual Growth Rate 12.4%
Regions Covered Global

Key Topics Covered:

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Macroeconomic Factor Analysis
  • Impact of U.S. Tariffs on the Pharmaceutical Industry
  • Healthcare Expenditure
  • Impact of GDP on the Pharma Sector
  • Porter’s Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Potential for New Entrants
  • Threat of Substitutes
  • Competitiveness in the Industry

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Chronic Diseases
  • Increasing R&D Spending by Market Players
  • Rise in Government Funding and Pharmaceutical R&D Spending
  • Market Restraints
  • High Cost of Immunotherapy Drugs
  • Rising Generic Competition
  • Lack of Skilled Professionals
  • Market Opportunities
  • Technological Advances in Immunotherapy
  • Potential in Immunotherapy

Chapter 4 Regulatory Landscape

  • Overview
  • U.S.
  • Europe
  • Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

  • Overview
  • AI and ML
  • Emergent Biomarkers
  • Genome Editing and CRISPR
  • Pipeline Analysis
  • Key Takeaways
  • Patent Analysis
  • Key Takeaways

Chapter 6 Market Segment Analysis

  • Segmentation Breakdown
  • Global Market for Immunotherapy Drugs, by Therapy Type
  • Key Takeaways
  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Cytokines
  • Others
  • Global Immunotherapy Drug Market, by Application
  • Key Takeaways
  • Cancer
  • Autoimmune Diseases
  • Chronic Inflammatory Respiratory Condition
  • Geographic Breakdown
  • Global Market for Immunotherapy Drugs by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 7 Competitive Intelligence

  • Key Takeaways
  • Competitive Landscape
  • Company Share Analysis

Chapter 8 Sustainability in Immunotherapy Drugs Market: An ESG Perspective

  • Introduction to ESG
  • Sustainability in the Immunotherapy Drug Market
  • ESG Perspective
  • Environmental Impact
  • Social Impact
  • Governance Impact
  • ESG Risk Ratings
  • Conclusion

For more information about this report visit https://www.researchandmarkets.com/r/qypknq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Posted on by

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026




Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.


About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Posted on by

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer




Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

Litten, Jason

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) —  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.

“We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes,” said Thomas Zindrick, President, CEO, and Chairman of the Board. “He brings extensive experience in oncology drug development of innovative therapies, including a proven track record of leading complex programs from early development through late-stage trials. Jason’s insight and disciplined approach to clinical execution will support our momentum as we approach key readouts in ovarian and lung cancer and work to unlock the full clinical and commercial potential of Olvi-Vec as a best-in-class immunotherapy.”

Dr. Litten is a seasoned biopharmaceutical executive with over 20 years of experience spanning academia, large pharmaceutical organizations, and innovative biotechnology companies. He has led the design, execution, and interpretation of Phase 1-4 clinical trials in liquid and solid tumors, with expertise across biologics, small molecules, and cellular therapies.

Most recently, Dr. Litten served as Chief Medical Officer at Chimeric Therapeutics, Ltd., where he advanced first-in-human cell therapy programs in brain, gastrointestinal, and hematologic cancers. Prior to that, he was Chief Medical Officer at Artiva Biotherapeutics, Inc., where he built and led clinical development, operations, regulatory affairs, quality, and medical affairs functions. Earlier in his career, Dr. Litten held senior leadership roles at Optera Therapeutics Corp., Juno Therapeutics, Inc., Clovis Oncology, Inc., and Amgen Inc., contributing to global development strategies for novel oncology therapeutics.

Dr. Litten earned an M.D. from Emory University School of Medicine and a B.S. in Finance and Economics from Cornell University. He completed postdoctoral training in Pediatric Hematology & Oncology at the University of Texas Southwestern Medical Center at Dallas and is licensed as a physician and surgeon in California.

“I am honored to join Genelux at such a pivotal time,” said Dr. Litten. “Olvi-Vec represents a compelling therapeutic platform with potential across multiple tumor types, and I look forward to working with the team to execute our clinical strategy, prepare for future regulatory interactions, and ultimately bring new options to patients facing difficult-to-treat cancers.

In connection with his appointment, Dr. Litten was granted an inducement award of a stock option to purchase 275,000 shares of common stock under Genelux’s 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), at an exercise price per share equal to the closing price of Genelux’s common stock on The Nasdaq Capital Market on the date of grant. The inducement award will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to Dr. Litten’s continued service relationship with the company through the applicable vesting dates.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician’s choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician’s choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux’s discovery and development efforts revolves around its proprietary CHOICE™ platform from which the company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan,” “look forward” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to Dr. Litten’s expected contribution to Genelux, Olvi-Vec’s development plans and the realization of Olvi-Vec’s full potential. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Investor Contact

Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com

Media Contact

Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com

Source: Genelux Corporation

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4196792-0f6a-456e-b165-1a9302b7e413

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Posted on by

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET




BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.

Dr. Legare will provide an overview of achondroplasia, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating infigratinib as a treatment for skeletal dysplasia, including achondroplasia. Dr. Legare actively engages with leading professional organizations, including the American Academy of Pediatrics, the Society for Pediatric Research, the American College of Medical Genetics, Little People of America, and the International Skeletal Dysplasia Society, and holds an affiliate appointment in the Department of Neurological Surgery. Her clinical expertise spans the diagnosis, management, and long-term care of children with skeletal dysplasia.

In addition to Dr. Legare, executive members of the skeletal dysplasia program team will review the ongoing infigratinib clinical development program and discuss the ongoing Phase 3 PROPEL 3 study, for which topline results are expected in Q1 2026.

To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch

Posted on by

Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch




Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch

MONTREAL, Québec, Jan. 02, 2026 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce preliminary success in the Québec provincial vape cartridge category launch. Estimated retail sales data indicates multiple leadership positions across the nascent category (for the months November and December 2025), with a 29.7% category share by retail sales value1.

The success of the vape category launch also advanced Cannara to a #1 market share position by retail sales in Quebec for the month of December 2025, with a 14.7% share of cannabis retail sales in the province, a 100-basis point improvement month over month2.

“The vape cartridge category launch in our home province of Québec has been a valuable opportunity to further expand our position as Canada’s #1 premium vape producer. With 5 of the 25 total SKUs approved, we successfully positioned our business for the largest product category launch in recent Canadian cannabis history, and I am encouraged at the strong initial consumer demand for our premium vapes,” said Zohar Krivorot, President & CEO of Cannara.

“Our highly advanced, vertically-integrated platform enabled the creation of truly premium, best-in-class products for Québec’s newly launched vape category. We are pleased to see strong reception to the launch of our first-ever rosin vape cartridge offerings, alongside our already nationally leading premium live resin vapes. We look forward to the continued consumer adoption of the category,” said Nicholas Sosiak, Chief Financial Officer of Cannara.

Cancellation and Re-Issuance of Previously Granted Stock Options

The Company also announces that, on December 31, 2025, its board of directors approved the cancellation and re-issuance of certain previously granted stock options to certain officers, directors and employees of the Company (the “Affected Options”) in connection with the administration of the Company’s equity compensation plans. The grant of the Affected Options was originally announced in news releases issued by the Company on September 1, 2025, and November 24, 2025.

The Company determined that, due to an administrative oversight, the issuance of the Affected Options resulted in the Company exceeding the limits permitted under its stock option plan (the “Stock Option Plan”) and restricted share unit compensation plan (the “RSU Plan”), each of which is currently a rolling plan permitting the issuance of up to 10% of the Company’s issued and outstanding common shares. The Affected Options were cancelled and are to be re-issued on January 2, 2026, with substantially the same terms and conditions, including the same exercise prices, with vesting schedules and expiry dates intended to remain unchanged and to continue as if originally granted.

A total of 544,600 stock options were cancelled and re-issued, including 515,000 stock options held by directors and officers of the Company. Amongst the cancelled and re-issued options held by insiders of the Company, 500,000 have an exercise price of $1.44 expiring on August 27, 2035, and 15,000 have an exercise price of $1.80 expiring on November 20, 2032. The cancellation and re-issuance were undertaken solely to address the administrative oversight and did not result in any net increase of stock options outstanding under the Stock Option Plan.

As disclosed in the Company’s management proxy circular dated December 18, 2025 (the “Circular”), in connection with a review of the Company’s security-based compensation arrangements and certain housekeeping changes undertaken to align the Stock Option Plan with governance practices applicable to senior Canadian stock exchanges, the Company is seeking shareholder approval at its annual general and special meeting to be held on January 29, 2026, to amend and convert the Stock Option Plan and the RSU Plan from rolling plans to fixed security-based compensation plans. The proposed amendments are intended to provide greater administrative clarity and facilitate ongoing compliance with plan limits.

Following implementation of the proposed amendments, the aggregate number of listed shares issuable under both plans will be fixed at 15% of the Company’s issued and outstanding listed shares as at the date of shareholder approval. The TSX Venture Exchange has provided conditional approval of the amended Stock Option Plan and amended RSU Plan, subject to shareholder approval. Copies of the amended plans are appended to the Circular.

The Circular and proxy-related materials are available on the Company’s website at https://www.cannara.ca/en/investor-area/ and under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Accelerated Vesting of RSUs

In addition, the Company announces that, on December 31, 2025, its board of directors approved the accelerated vesting of 15,000 restricted share units previously granted to the late Jack Kay, a former director and officer of the Company, effective December 31, 2025, to ensure compliance with the terms of the RSU Plan following his passing on November 8, 2025.

CONTACT

Nicholas Sosiak, CPA, CA
Chief Financial Officer
nick@cannara.ca 		 Zohar Krivorot 
President & Chief Executive Officer 
zohar@cannara.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ABOUT CANNARA

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.

CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION

This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements with respect to vape category launch in Quebec.

Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, anticipated product offerings, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company’s ability to become a leader in the field of cannabis cultivation, production, and sales.

In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.

Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.
___________________________________________

1 (Weedcrawler data, November 2025 to December 2025, https://weedcrawler.ca)
2 (Weedcrawler data, December 2025, https://weedcrawler.ca)

Nova Leap Health Corp. Announces Promotion of Melissa Anderson to Senior Vice President, United States

Posted on by

Nova Leap Health Corp. Announces Promotion of Melissa Anderson to Senior Vice President, United States




Nova Leap Health Corp. Announces Promotion of Melissa Anderson to Senior Vice President, United States

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

HALIFAX, Nova Scotia, Jan. 02, 2026 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing provider of home-based and community-based care services in North America, is pleased to announce the promotion of Melissa Anderson from her role as Vice President, Operations (U.S.) to Senior Vice President (U.S.), effective January 1, 2026.

Ms. Anderson joined Nova Leap in 2018 and has played a central role in advancing the Company’s U.S. operations through disciplined execution, operational improvements, strengthened regional leadership structures, and EBITDA growth across the division. In her expanded role, Melissa will oversee Nova Leap’s U.S. home care operations, including strategic planning, operational performance, expansion into new states, and integration of new service lines, including the Company’s recently launched Care Management division.

“Melissa has demonstrated exceptional leadership and operational discipline throughout her tenure,” said Chris Dobbin, President & CEO. “Her promotion reflects both her strong performance and the increasing scale and complexity of our U.S. business. As we continue to grow through new locations, acquisitions and additional service lines across the continuum of care, Melissa’s leadership will be instrumental in driving execution and long-term value.”

“I am honoured to continue serving Nova Leap in this expanded capacity,” said Ms. Anderson. “Our U.S. team is deeply committed to delivering compassionate, high-quality care in communities across the country. I look forward to supporting our growth strategy and strengthening our operations to better serve our clients, families, and partners.”

Nova Leap continues to expand its footprint across the United States and Canada through disciplined growth, including targeted acquisitions and de novo expansion supported by scalable infrastructure.

About Nova Leap

Nova Leap is a healthcare services company delivering home-based and community-based care across North America. Through its network of local agencies, the Company provides personal care, dementia care, and companion services that enable individuals to live safely and independently at home. Nova Leap’s Care Management division extends its role across the continuum of care by offering coordinated, technology-enabled support that helps families navigate complex medical, cognitive, and social needs. Combining disciplined operations, data-driven decision-making, and compassionate service, Nova Leap is committed to improving outcomes for clients and communities while advancing sustainable, scalable models of community care.

FORWARD LOOKING INFORMATION:

Certain information in this press release may contain forward-looking statements, such as statements regarding future expansions, development of the Care Management division, anticipated geographic and organic growth, and potential acquisition opportunities. This information is based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are made as of the date of this release, and the Company assumes no obligation to update them except as required by applicable securities laws. Additional risk factors are detailed in the Company’s filings with Canadian securities regulators at www.sedarplus.com.

CAUTIONARY STATEMENT:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information:

Chris Dobbin, CPA, ICD.D
Director, President and CEO
P: 902-401-9480    
E:cdobbin@novaleaphealth.com

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Posted on by

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance




Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

– Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million –

– Ended Q4 2025 with greater than $200 million in cash and cash equivalents –

BOSTON–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026.


“Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming quarters,” said Tom McCourt, chief executive officer of Ironwood. “As we close 2025, we are on track to achieve the low-end of our full-year LINZESS U.S. net sales and total revenue guidance ranges and ended the fourth quarter with greater than $200 million in cash and cash equivalents. Also, in the fourth quarter we met with the FDA to align on a confirmatory Phase 3 trial design of apraglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF). Based on this meeting, we are on track to initiate a confirmatory trial in the first half of 2026 and expect to provide details on the trial design in our fourth quarter and full-year 2025 update later this quarter.”

“In 2026, we remain focused on our core priorities of maximizing LINZESS, advancing apraglutide and delivering sustained profits and cash flows. We believe our full-year 2026 guidance demonstrates the significant progress we’ve made to deliver on these priorities to help drive value for shareholders moving forward. Effective January 1, 2026, the LINZESS list price has been lowered in response to evolving health care dynamics and to support ongoing patient access. In turn, we expect higher net sales in 2026 for LINZESS year-over-year, specifically driven by the elimination of the inflationary component of statutory required rebates across channels, including Medicaid, due to the decrease in list price. In conjunction with the anticipated increased net sales, we expect our continued focus on disciplined expense management to result in greater than $300 million in adjusted EBITDA in 2026. Finally, we continue to progress our previously announced strategic alternatives review in an effort to maximize shareholder value and look forward to providing further updates as appropriate,” added Tom McCourt.

Financial Guidance

Ironwood is maintaining its previous FY 2025 financial guidance and is providing FY 2026 financial guidance.

 

FY 2025 Guidance

(November 2025)

FY 2026 Guidance

(January 2026)

LINZESS U.S. net sales

$860 – $890 million

$1.125 – $1.175 billion

Driven by improved net price and low-single digit percentage demand growth

Total revenue1

$290 – $310 million

$450 – $475 million

Adjusted EBITDA2

>$135 million

>$300 million

1 Ironwood’s U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood’s commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue guidance accounts for the impact of the reduction to Ironwood’s commercial expenses and corresponding reimbursement from AbbVie due to Ironwood’s strategic reorganization announced in January 2025.

2 Adjusted EBITDA is calculated by subtracting restructuring expenses, net interest expense, income taxes, depreciation and amortization and stock-based compensation, from GAAP net income. The exclusion of stock-based compensation from Adjusted EBITDA represents an update to our definition of Adjusted EBITDA, effective in the first quarter of 2025. For purposes of this guidance, we have assumed that Ironwood will not incur material expenses related to business development activities in 2025 and 2026. Ironwood does not provide guidance on GAAP net income or a reconciliation of expected adjusted EBITDA to expected GAAP net income because, without unreasonable efforts, it is unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA. These adjustments are uncertain, depend on various factors and could have a material impact on GAAP net income for the guidance period. Management believes this non-GAAP information is useful for investors, taken in conjunction with Ironwood’s GAAP financial statements, because it provides greater transparency and period-over-period comparability with respect to Ironwood’s operating performance. These measures are also used by management to assess the performance of the business. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.

About LINZESS (Linaclotide)

LINZESS® is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data.

LINZESS is a once-daily capsule that helps relieve the abdominal pain and constipation, associated with IBS-C in adults and pediatric patients 7 years of age and older. LINZESS has also been shown to relieve constipation, infrequent stools, hard stools, straining, and incomplete evacuation associated with CIC in adult patients. LINZESS relieves constipation in children and adolescents aged 6 to 17 years with functional constipation.

LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.

In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood’s partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with AstraZeneca for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.

LINZESS Important Safety Information

INDICATIONS AND USAGE

LINZESS® (linaclotide) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older and for the treatment of chronic idiopathic constipation (CIC) in adults and for the treatment of functional constipation (FC) in children and adolescents 6 to 17 years of age.

IMPORTANT SAFETY INFORMATION

  • WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE
  • LINZESS is contraindicated in patients less than 2 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.

Contraindications

  • LINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

  • LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration. There was no age dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients.

Diarrhea

  • In adults, diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients and in <1% of 72 mcg LINZESS-treated CIC patients.
  • In pediatric patients, diarrhea was also the most common adverse reaction of LINZESS-treated patients in IBS-C and FC clinical trials. In two double-blind trials, diarrhea was reported in 4% of pediatric patients 6 to 17 years of age with FC treated with LINZESS 72 mcg once daily, and 7% and 8% of pediatric patients 7 to 17 years of age with IBS-C treated with LINZESS 145 mcg and 290 mcg once daily, respectively. In clinical trials, severe diarrhea was reported in one pediatric patient with FC treated with LINZESS 72 mcg once daily and in one pediatric patient with IBS-C treated with LINZESS at a dosage higher than the recommended 145 mcg once daily dosage for IBS-C.

Common Adverse Reactions (incidence ≥2% and greater than placebo)

  • In IBS-C or CIC adult patients: diarrhea, abdominal pain, flatulence, and abdominal distension.
  • Most common adverse reaction reported in pediatric patients with FC or IBS-C is diarrhea.

Please see full Prescribing Information including Boxed Warning:

https://www.rxabbvie.com/pdf/linzess_pi.pdf

LINZESS® and CONSTELLA® are registered trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s ability to execute on its mission; Ironwood’s strategy, business, financial position and operations; Ironwood’s ability to drive growth and profitability; the commercial potential of LINZESS; Ironwood’s financial performance and results, and guidance and expectations related thereto; LINZESS prescription demand growth, LINZESS U.S. net sales growth, total revenue and adjusted EBITDA in 2025 and 2026; our belief that the 2026 financial guidance demonstrates a significant progress made to help drive value for shareholders; our plan to continue to progress apraglutide and initiate a confirmatory Phase 3 trial and our expectation and timing to provide additional details on the trial design and to initiate such trial; and the status of the strategic alternatives review and timing to provide an update. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, and our other product candidates; the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products’ commercial success; the risk that clinical programs and studies, including for linaclotide pediatric programs and apraglutide, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical studies and clinical trials may not be replicated in later trials and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the risk that we are unable to execute on our strategy to in-license externally developed products or product candidates; the risk that we are unable to successfully partner with other companies to develop and commercialize products or product candidates; the risk that healthcare reform and other governmental and private payor initiatives may have an adverse effect upon or prevent our products’ or product candidates’ commercial success; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of any of our linaclotide pediatric programs and/or apraglutide is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood’s or AbbVie’s accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could adversely affect our financial condition or restrict our future operations; the risk that our activities to explore potential strategic alternatives may not result in any transaction or maximize shareholder value; and the risks listed under the heading “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our subsequent Securities and Exchange Commission filings.

Contacts

Company:
Greg Martini

Chief Financial Officer

gmartini@ironwoodpharma.com

Investors:
Precision AQ (formerly Stern Investor Relations)

Stephanie Ascher

Stephanie.Ascher@precisionaq.com

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

Posted on by

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference




Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026.


The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PST/10:30 a.m. ET.

The event will be webcast simultaneously at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the conclusion of the event.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com